Login to Your Account

Allena raises $25M series B for phase II study in kidney disease

By Randy Osborne
Staff Writer

Thursday, December 4, 2014

Aiming to cover the landscape of hyperoxaluria Allena Pharmaceuticals Inc. raised $25 million in a series B financing.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription